The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8

被引：0
|
作者：
Jakesz, R [1 ]
Gnant, M [1 ]
Greil, R [1 ]
Tausch, C [1 ]
Samonigg, H [1 ]
Kwasny, W [1 ]
Kubista, E [1 ]
Stierer, M [1 ]
Luschin, G [1 ]
Mittlboeck, M [1 ]
机构：
[1] Vienna Med Sch, Vienna, Austria
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 50 条
  • [41] A cost-effectiveness analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with early-stage breast cancer in Mexico
    Mould-Quevedo, J.
    Tapia-Valencia, J.
    Davila-Loaiza, G.
    VALUE IN HEALTH, 2007, 10 (03) : A124 - A125
  • [42] Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population
    Howell, A.
    Forbes, J.
    Cuzick, J.
    BREAST, 2009, 18 : S51 - S51
  • [43] Endocrine effects of adjuvant letrozole versus tamoxifen in hormone responsive postmenopausal early breast cancer patients: results from the HOBOE randomized trial
    Morabito, A.
    Rossi, E.
    Di, Rella F.
    Esposito, G.
    Gravina, A.
    Labonia, V
    Landi, G.
    Nuzzo, F.
    Pacilio, C.
    De Maio, E.
    Piccirillo, M. C.
    De Feo, G.
    D' Aiulo, G.
    Botti, G.
    Gallo, C.
    Perrone, F.
    de Matteis, A.
    CANCER RESEARCH, 2009, 69 (02) : 151S - 151S
  • [44] Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
    Locker, Gershon Y.
    Mansel, Robert
    Cella, David
    Dobrez, Deborah
    Sorensen, Sonja
    Gandhi, Sanjay K.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (02) : 229 - 238
  • [45] Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
    Gershon Y. Locker
    Robert Mansel
    David Cella
    Deborah Dobrez
    Sonja Sorensen
    Sanjay K. Gandhi
    Breast Cancer Research and Treatment, 2007, 106 : 229 - 238
  • [46] Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21).
    Braun, S.
    Naume, B.
    Mueller, E.
    Janni, W.
    Marth, C.
    Gnant, M. F.
    CANCER RESEARCH, 2009, 69 (02) : 297S - 298S
  • [47] Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
    Tomohiko Aihara
    Isao Yokota
    Yasuo Hozumi
    Kenjiro Aogi
    Hiroji Iwata
    Motoshi Tamura
    Atsushi Fukuuchi
    Haruhiko Makino
    Ryungsa Kim
    Masashi Andoh
    Koichiro Tsugawa
    Shinji Ohno
    Takuhiro Yamaguchi
    Yasuo Ohashi
    Toru Watanabe
    Yuichi Takatsuka
    Hirofumi Mukai
    Breast Cancer Research and Treatment, 2014, 148 : 337 - 343
  • [48] Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects
    Jonat, W
    Hilpert, F
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (06) : 343 - 355
  • [49] Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects
    Walter Jonat
    Felix Hilpert
    Journal of Cancer Research and Clinical Oncology, 2006, 132 : 343 - 355
  • [50] Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
    Aihara, Tomohiko
    Yokota, Isao
    Hozumi, Yasuo
    Aogi, Kenjiro
    Iwata, Hiroji
    Tamura, Motoshi
    Fukuuchi, Atsushi
    Makino, Haruhiko
    Kim, Ryungsa
    Andoh, Masashi
    Tsugawa, Koichiro
    Ohno, Shinji
    Yamaguchi, Takuhiro
    Ohashi, Yasuo
    Watanabe, Toru
    Takatsuka, Yuichi
    Mukai, Hirofumi
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (02) : 337 - 343
12345